Muscle weakness in heart failure
Target validation,
Drug discovery / Therapeutics
Heart failure is thought to affect around 1 million people in the UK. Many patients with heart failure have severe muscle weakness but no effective drug treatments are available.
This team have previously discovered that a high level of a protein called MuRF1 may have an important role in this muscle weakness.
This project will further investigate the involvement in MuRF1 in heart failure-induced muscle weakness and aims to identify new drug treatments for loss of muscle strength. If effective, this will improve symptoms, quality of life and survival in heart failure patients.
The development of a new AI-supported model for imaging the heart based on data from over 700 people with atrial fibrillation, allow ablation to be more personalised to individual patients.
Bringing together patients and medical professionals to establish a partnership aimed at identifying areas of priority in adult cardiac surgery, to better inform clinicians and make heart surgery safer for patients.
Developing an AI-assisted computer programme to identify whether a conduction system pacing (CSP) procedure has been successful, which will allow more patients to benefit from this innovative pacemaker technology.
Developing a new test to measure the levels of desmosine in the body, which are higher when there is damage to the aorta, to diagnose aortic dissection more quickly.
Your gifts fund our life saving project